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Abstract
Background: Ecteinascidin 743 (Et 743), a natural product
derived from a marine tunicate, is a potent antitumor agent
presently in phase II clinical trials. Et 743 binds in the minor
groove of DNA and alkylates N2 of guanine via a unique
mechanism involving catalytic activation. The sequence selectivity
of Et 743 is governed by different patterns of hydrogen-bonding to
DNA, which results in differential reversibility of the covalent
adducts. As determined by nuclear magnetic resonance spectros-
copy, the preferred sequences 5P-PuGC and 5P-PyGG are
stabilized by a hydrogen-bonding network, while the non-
preferred sequences 5P-NG(A/T) are much less stabilized due to
the lack of a key hydrogen bond to the GC base pair on the 3P-side
of the alkylated guanine.
Results : Mammalian cell lines (XPB, XPD, XPF, XPG, and
ERCC1) deficient in the nucleotide excision repair (NER) gene
products show resistance to Et 743. The recognition and
subsequent incision of Et 743^DNA adducts by the bacterial
multisubunit endonuclease UvrABC were used to evaluate DNA
repair-mediated toxicity as a rationale for the resistance of NER-
defective cell lines and the antitumor activity of Et 743. The Et
743^DNA adducts are indeed recognized and incised by the
UvrABC repair proteins ; however, the pattern of incision
indicated that the non-preferred, and less stable, sequences (i.e.
5P-NG(A/T)) modified with Et 743 are generally incised at a much
higher efficiency than the preferred, more stable sequences (i.e. 5P-
PuGC or 5P-PyGG). In addition, within the same Et 743
recognition sequence, the level of incision varies, indicating that
flanking regions also contribute to the differential incision
frequency.
Conclusions: The inefficient repair incision by the UvrABC
nuclease of Et 743^DNA adducts provides a basis for rationalizing
the observed repair-dependent cytotoxicities of these DNA
adducts, if other associated structural properties of Et 743^DNA
adducts are taken into account. In particular, the wedge-shaped Et
743, which forces open the minor groove of DNA, introducing a
major groove bend, and the extrahelical protrusion of the C-
subunit of Et 743 provide unique characteristics alongside the
hydrogen-bonding stabilization of a covalent DNA adduct, which
we propose traps an intermediate in NER processing of Et 743^
DNA adducts. This trapped intermediate protein^Et 743^DNA
adduct complex can be considered analogous to a poisoned
topoisomerase I^ or topoisomerase II^DNA complex. In the
absence of an intact NER nuclease complex, this toxic lesion is
unable to form, and the Et 743^DNA adducts, although not
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repaired by the NER pathway, are less toxic to cells. Conversely,
elevated levels of either of these nucleases should lead to enhanced
Et 743 toxicity. ß 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The ecteinascidins (Ets) are extremely potent antitumor
agents isolated from the marine tunicate Ecteinascidia tur-
binata [1]. Of the numerous Ets that have been isolated, Et
743 is the ¢rst to advance to clinical trials, where it is
particularly active against soft tissue sarcomas [2^6]. Et
743 is a carbinolamine-containing antitumor agent com-
posed of three fused tetrahydroisoquinoline rings and is
structurally related to the DNA-reactive saframycins [7^9],
naphthyridinomycin [10], and anthramycin [11] (Fig. 1A).
The primary structural di¡erence between the saframycins
and Et 743 is that Et 743 contains an extra tetrahydroiso-
quinoline ring, the C-subunit, that is absent in this other
antitumor antibiotic. While the A- and B-subunits of Et
743 provide the sca¡old for DNA recognition and bond-
ing, the C-subunit protrudes out of the minor groove,
making only limited contacts with the DNA [12] (Fig.
2A). Like the other carbinolamine antibiotics, the Ets
bond in the minor groove of DNA in a sequence-depen-
dent manner and alkylate the N2 position of guanine [13].
Et 743^DNA adduct formation is mediated through an
intramolecular acid-catalyzed dehydration of the carbinol-
amine moiety, resulting in an iminium intermediate that is
the DNA-reactive species (Fig. 2B) [14].
Through gel mobility shift assays [13] and high-¢eld
nuclear magnetic resonance (NMR) studies [12,15], the
preferred thermodynamic sequence of Et 743 has been
shown to be 5P-PuG*C and 5P-PyG*G (* indicates the
covalently modi¢ed guanine), while the non-preferred se-
quences are 5P-NG*(A/T). The Et 743^DNA hydrogen-
bonding network that stabilizes the adduct is a major fac-
tor in determining sequence recognition. The formation of
a hydrogen bond between one of the oxygens of the meth-
ylenedioxy ring of Et 743 and a proton in the exocyclic 2-
amino group of the guanine located 3P to the alkylated site
on either strand (HB2 in Fig. 1B) largely determines if the
bonding sequence yields a stable DNA adduct. Elimina-
tion of this hydrogen bond acceptor by replacing the 3P G
or C with an A or T makes the sequence less stable [16].
We have recently shown that the relative stabilities of the
Et 743^DNA covalent adducts determine the rate of the
Et 743^DNA covalent adduct reverse reaction, while the
rate of the forward reaction is independent of the £anking
sequence [16]. Hence, the sequence selectivity of Et 743 is
determined by the relative kinetics of the covalent reversal
reaction, which leads to the release of free Et 743 and
rebonding at the same or di¡erent sequences (Fig. 2B).
The net e¡ect of this process is the time-dependent chan-
neling of Et 743 to a subset of DNA sequences in which
the Et 743^DNA adducts are thermodynamically stable.
Thus, during a 6-h incubation, 20% of the initial covalent
adduct at the less stable sequence migrates to the stable
sequence (5P-PuG*C and 5P-PyG*G).
Et 743 has shown promising activity in phase I and II
clinical trials, particularly in soft tissue sarcomas, which
sets it apart from other minor groove DNA monoalkylat-
ing agents [17,18]. One very unique feature of this agent is
that it is the ¢rst example of a minor groove alkylating
agent that bends DNA toward the major groove [19]. In
addition, other factors, such as the sequence-dependent
hydrogen-bonding interactions between Et 743 and the
minor groove of DNA and the protrusion of the C-sub-
unit from the minor groove, may also contribute to the
biological activity of Et 743 [15]. However, the biologically
relevant macromolecular targets have not been fully deter-
mined. The ¢rst proposed target was topoisomerase I,
which forms protein^DNA cross-links in the presence of
Et 743 [20,21]. More recently, evidence was presented that
shows that Et 743 can interfere with transcription activa-
tion of the MDR1 gene [22]. The Pommier laboratory has
now provided compelling evidence that eukaryotic XPG-
defective cells are resistant to Et 743 [23], and the D’In-
calci group has shown that XPF^ERCC1-defective cells
are also resistant to Et 743 [24]. In this contribution we
have tested a panel of eukaryotic cell lines defective in the
nucleotide excision repair (NER) pathway for sensitivity
to Et 743 and found that they are more resistant than the
parent wild-type cell line. To gain further insight into this
unexpected result, we have used the bacterial UvrABC
nuclease system to characterize how the NER pathway
recognizes and repairs Et 743^DNA adducts that di¡er
in their hydrogen-bonding-induced stability in the DNA
helix. Signi¢cantly, Et 743^DNA adducts at di¡erent se-
quences, with inherently di¡erent stabilities, are repaired
at di¡erent e⁄ciencies. Speci¢cally, the sequences at which
Et 743 forms less stable, more dynamically £exible DNA
adducts (e.g. at 5P-AGT) are the sites at which repair in-
cision is the most e⁄cient, while the more stable and con-
formationally rigid Et 743^DNA lesions are not as readily
incised. In both cases this can lead to aberrant or un-
coupled 3P or 5P incisions. This decrease in incision e⁄-
ciencies at the preferred DNA sequences (e.g. 5P-AGC)
compared to the non-preferred sequences (e.g. 5P-AGT)
may be explained by de¢ned di¡erences in DNA structure
and dynamics induced by binding Et 743 at these di¡erent
bonding sites. We propose that the ine⁄cient incision re-
pair is related to the repair-dependent toxicities previously
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demonstrated in mammalian cells [23,24]. A model is pro-
posed for how the bacterial UvrABC nuclease handles Et
743^DNA adducts at the preferred and non-preferred
bonding sequences, which rationalized the NER-depen-
dent toxicity observed in mammalian cells. While the com-
plexity of NER in bacteria and mammalian cells is clearly
di¡erent, with a larger patch and more proteins involved
in the mammalian NER, it is believed that both systems
have much in common.
2. Results
2.1. Mutant cell lines de¢cient in the transcriptionally
coupled NER pathway are more resistant to Et 743
than to their isogenic parent cell line
Both the Pommier [23] and the D’Incalci [24] laborato-
ries have reported that NER-defective cell lines (XPG^
and XPF^ERCC1, respectively) are more resistant to Et
Fig. 1. A: Structures of Et 743, saframycin A, naphthyridinomycin, and anthramycin. Carbinolamines are indicated by a dashed line. A-, B-, and C-
subunits of Et 743 and saframycin A are shaded blue, green, and orange, respectively. B: The hydrogen-bonding (HB1^HB4) interaction of Et 743 co-
valently bound with DNA. HB1^HB3 make direct contacts with the 3-bp DNA target sequence. The direction of arrows refers to hydrogen bond donor
to acceptor. In the case of the 5P-AGT sequence, HB2 is lost. The enlarged area shows the HB2 hydrogen-bonding between O18 and the exocyclic 2-
amino group of guanine on the 3P-side of the covalent adduct site.
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743 than to their isogenic parent cell lines. The results in
Fig. 3 demonstrate that all of the mammalian NER-defec-
tive cell lines (XPB, XPD, XPF, XPG, and ERCC1) show
about a ¢ve-fold greater resistance to Et 743 than the
Chinese hamster ovary parent cell line (AA8). Of these
cell lines, ERCC1 and XPG are more resistant, thus con-
¢rming the previous results but extending this observation
to all these genes involved in transcriptionally coupled
events. Of the other carbinolamine antibiotics shown in
Fig. 1B, only anthramycin has been tested for DNA re-
pair. In this case, single- and double-strand breaks were
found to be excision repair-dependent [25].
Fig. 2. A: A molecular dynamics-generated structure of Et 743 at the preferred bonding site. The three Et 743 subunits A (green), B (yellow), and C
(white) are positioned in the minor groove of DNA. B: Reversible reaction of Et 743 with DNA to form the Et 743^N2-guanine^DNA adduct. ‘B’ is a
DNA base hydrogen bond acceptor (adapted from [16]).
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2.2. Et 743^DNA adducts are recognized and incised by
UvrABC nuclease, although at high Et 743
concentrations, the ability of the protein complex to
incise these lesions is inhibited
Since the NER pathway repairs the majority of com-
pounds that covalently modify DNA (for reviews see [26^
28] and references therein), and this pathway seems to be
detrimental to cellular viability in the presence of Et 743
[23,24], we thought it would be pertinent to determine the
ability of the UvrABC nuclease to recognize and incise Et
743^DNA adducts. A restriction enzyme fragment from
the adenine phosphoribosyltransferase (APRT) gene modi-
¢ed with various concentrations of Et 743 was incubated
with the UvrABC proteins, and the digested substrates
were analyzed on a denaturing gel. The UvrABC incision
step at the 5P- or 3P-side of the Et 743^DNA adducts can
be monitored by radiolabeling the DNA substrate on ei-
ther the 5P- or 3P-side, respectively. The UvrABC cleavage
pattern of the 5P- and 3P-end-labeled DNA fragments from
the APRT gene shows that Et 743^DNA adducts are in-
deed recognized and incised by UvrABC nuclease (Fig.
4A). Notably, the ability of UvrABC nuclease to incise
the Et 743^DNA adducts becomes inhibited at the higher
Et 743 concentrations (lanes 10 and 11, left and right
panels). This phenomenon has been shown with other
DNA-interactive compounds such as mitomycin C [29],
anthramycin [30], and CC-1065 [31]. One possible explana-
tion for this result is that multiple Et 743^DNA lesions in
close proximity distort DNA, thereby preventing the
UvrABC nuclease from processing the lesion. A second
possibility, which we favor, is that Et 743^DNA adducts
could sequester one or more of the UvrABC proteins,
rendering them unavailable to e⁄ciently recognize and in-
cise subsequent Et 743^DNA lesions.
2.3. UvrABC incision frequency of DNA-containing Et 743
adducts is dependent upon sequence context, where
adducts at the non-preferred Et 743 target sequences
(e.g. 5P-AGT) are incised more e⁄ciently than adducts
at the preferred sequences (e.g. 5P-AGC)
Further analysis of the cleavage patterns of Et 743-
modi¢ed DNA shows that strand breaks occur three or
four bases 3P to the modi¢ed guanine residue and six or
seven bases 5P to the modi¢ed guanine residue, which is
typical of UvrABC nuclease incision [26,27]. However,
quite clearly not all Et 743^DNA adducts are equally in-
cised by UvrABC, as is evident by the varying degrees of
the intensities of the strand breaks (Fig. 4A). The relative
intensities of each incision product were quanti¢ed for
both 3P- and 5P-sides of each Et 743^DNA adduct (above
and below the sequence in Fig. 4B). Intriguingly, the Et
743^DNA adducts at the non-preferred sequences (i.e. 5P-
AGT and 5P-TGT) are incised with the highest e⁄ciency,
whereas adducts at the preferred sequences (5P-AGC and
5P-TGC) were incised to a lesser extent (compare incision
bands 19 and 30 with bands 11 and 16 in Fig. 4B).
To increase the data set and con¢rm that Et 743^DNA
adducts at the non-preferred sequences are truly incised
more e⁄ciently than at the preferred sequences, we exam-
ined two other DNA restriction enzyme fragments : a 209-
bp fragment from the pCAT plasmid and a 200-bp seg-
ment from the pBR322 vector. Consistent with the pre-
vious results (shown in Fig. 4A,B), both of the new Et
743-modi¢ed restriction enzyme fragments showed inhibi-
tion of incision at high Et 743 concentrations and dis-
played di¡erential incision that was dependent upon the
immediate DNA £anking sequence (data not shown). The
intensities of the bands corresponding to the 3P and 5P
incision sites were scanned, and the relative intensities of
each band are shown above and below the sequences in
Fig. 4C,D, for each of the two DNA fragments. For the
most part, the guanines that render a strong 5P incision
band also render a strong 3P incision band. Again, the
most striking result is that the highest UvrABC incision
e⁄ciencies occur for the non-preferred DNA sequences
that form the unstable DNA adducts in both the pCAT
and pBR322 DNA fragments.
The data for all the UvrABC incision results have been
pooled and accumulated in Fig. 5. For the preferred and
non-preferred sequences (Fig. 5A,B), the e⁄ciency of each
3P and 5P incision was categorized into high, moderate, or
low. It is clear from a comparison of panels A and B in
Fig. 3. A: Percentage survival of Chinese hamster ovary parent cell line
(AA8) and the NER-defective lines (XPB, XPD, XPF, XPG, and
ERCC1) in the presence of increasing Et 743 concentrations. B: IC50
values for each cell line from (A).
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Fig. 5 that the Et 743^DNA adducts at non-preferred
sequences that lack the ability to form the HB2 hydrogen
bond (see Fig. 1B) are incised at a higher e⁄ciency than
those that can form the complete hydrogen bond network.
Adducts at the preferred alkylation sites that form the
HB2 hydrogen bond are incised with moderate to low
e⁄ciency (Fig. 5A), while adducts at the non-preferred
sequences display incision frequencies that are more
even, cutting at high, moderate, or low e⁄ciencies (Fig.
5B). In addition, about 25% of the preferred target se-
quences show no incision 5P or 3P to the Et 743^DNA
adduct, whereas all the non-preferred sites showed at least
3P or 5P incision. It is important to recognize that the
actual percentage of the Et 743 adducts that are incised
by UvrABC are not adjusted for the extent of modi¢ca-
tion of guanines to a given site. It is likely that the actual
percentage of Et 743-induced modi¢cation at the preferred
sequences is even higher than that at the non-preferred
target site, since the DNA adducts at these sites are
more stable at these sequences [16]. Thus, the actual extent
of di¡erence between incision frequency at preferred and
non-preferred sequences is likely to be underrepresented.
There is an apparent low frequency of uncoupled 3P or 5P
incisions for both preferred and non-preferred sequences
(usually less than 10%). We are hesitant to make too much
of the signi¢cance of this result because of its minor con-
tribution and because the absolute assignment of the 3P or
5P incisions can be sometimes confused by the aberrant 5P
cleavage bands observed in the site-directed Et 743^DNA
adducts.
2.4. The £anking sequence outside the 3-bp target sequence
(5P-NGN) may contribute to the e⁄ciency of incision
of Et 743^DNA adducts by UvrABC nuclease
Further inspection of the data in Figs. 5 and 6 demon-
strates that not all of the Et 743^DNA adducts at the
same 3-bp target sequence are incised at the same e⁄-
ciency, suggesting that more than just the 3-bp recognition
sequence is involved in determining the e⁄ciency of inci-
sion by the UvrABC nuclease. For example, the highest
level of incision occurs for a 5P-TGT lesion (site 30 in Fig.
4B) in the DNA fragment from the APRT gene, but Et
743^DNA adducts at other 5P-TGT sequences surrounded
by a di¡erent £anking sequence show di¡erent levels of
incision (compare incision sites 1, 2, 15, and 30 in Fig.
4B). In another example, a 5P-AGT adduct site placed
next to an A-tract was not incised e⁄ciently (compare
Fig. 4. A: Autoradiogram of UvrABC nuclease incision of an Et 743-modi¢ed 5P- or 3P-end-labeled 188-bp DNA fragment from the Chinese hamster
ovary APRT gene. Lanes 1^3, Maxam^Gilbert chemical sequencing reactions; lane 4 (control), DNA treated with 5 WM of Et 743; lane 5, unmodi¢ed
DNA treated with UvrABC; lanes 6^11, DNA modi¢ed with 0.25, 0.5, 1, 5, 15, and 20 WM of Et 743, respectively, in the presence of UvrABC. The Et
743 target sequence corresponding to the drug modi¢cation-induced UvrABC nuclease incision bands is shown on the right side of each panel. B: Rela-
tive intensities of UvrABC nuclease incision on the 3P- and 5P-sides of Et 743^DNA adducts in the 188-bp sequence from the APRT gene. The inten-
sities were normalized to 100% for the most intense band in each experiment. Arrows highlight some of the Et 743-modi¢ed AGC and AGT sequences
that are incised to varying degrees. C and D: Relative intensities of UvrABC nuclease incision on the 3P- and 5P-sides of Et 743^DNA adducts in the
209-bp fragment from pCAT plasmid (C) and the 200-bp fragment from pBR322 vector (D). The intensities were normalized to 100% for the most in-
tense band in each experiment. (b) indicates guanines that show no incision on either the 5P- or 3P-side of the Et 743^DNA adducts.
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incision sites 12 and 25 in Fig. 4C). While no obvious
consensus sequence could be inferred for identical Et 743
bonding sites that were e⁄ciently incised versus the adduct
sites that were poorly incised, we have shown previously
that certain sequences, such as an A-tract, can contribute
to the overall stability of Et 743^DNA adducts [16].
Therefore, it is not too surprising that the £anking region
beyond the 3-bp Et 743 recognition sequence also plays an
important role in determining the UvrABC e⁄ciency of
the incision process.
2.5. UvrABC nuclease displays anomalous DNA incision of
Et 743^DNA adducts showing an extra incision
product 11 or 13 bases 5P to the lesion
An Et 743-modi¢ed 64-bp fragment (see Fig. 6A,B) was
Fig. 4 (continued).
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used to study the UvrABC incision of a DNA duplex
containing either a centrally located 5P-AGC or 5P-AGT
sequence. Both 3P- and 5P-end-labeled fragments were used
on the (+) and (3) strands in these experiments. This Et
743 alkylation site is located within a central 22-bp seg-
ment that is made up entirely of AT base pairs. Due to the
self-complementarity of the region containing the 5P-AGC
sequence (Fig. 6A), there is an Et 743-reactive guanine in
the 5P-AGC sequence located on both the top and bottom
strands. As a result, Et 743 can modify either strand. Both
duplexes were modi¢ed with Et 743 followed by incuba-
tion with the UvrABC proteins, and the results are shown
in Fig. 6A,B.
Surprisingly, the UvrABC incision 5P to the Et 743^
Fig. 5. A and B: Summaries of the UvrABC nuclease incisions on the 5P- and 3P-sides of the Et 743^DNA adducts at the 5P-(NGGC ) and 5P-(NGAT ) 3-bp
recognition sequence. Numbers refer to the number of times the Et 743^DNA adduct was incised high, moderate, or low for a given recognition se-
quence. Each bar (expressed as a percentage) represents the number of times the non-preferred or preferred binding sites were incised high, moderate,
or low by UvrABC. The intensity of each band was normalized to the highest intensity band (100%). 1^20% is de¢ned as low, 21^44% is moderate,
and 45^100% is high.
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Fig. 6. Autoradiogram showing the 5P and 3P incisions of the 64-bp DNA oligonucleotide containing the (A) 5P-AGC or (B) 5P-AGT sequence. DNA
was modi¢ed with 0, 0.5, 1, 2.5, 5, or 10 WM (lanes 3^8) of Et 743 followed by incubation with UvrABC. Arrows denote the sites of UvrABC incision.
(*) indicates the 5P-AGC and 5P-AGT alkylation sites of Et 743. AG and TC refer to the Maxam^Gilbert sequencing lanes. The other sites of incision
arise from other Et 743^DNA alkylation sites. The full 64-bp sequence, with the bonding site highlighted and incision sites shown by arrows, whose
lengths correspond to intensity of cleavage, is shown at the bottom of each panel.
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DNA adduct is not the same for both strands. As ex-
pected, the 5P incisions for the top and bottom strands
occurred six bases from the adduct; however, 5P incisions
also occurred 11 and 13 bp from the adduct on the top
strand (Fig. 6A, left panel). The 3P incision occurred four
bases away from the site of the Et 743^DNA lesion for
both strands (Fig. 6A, right panel). That the intensity of
the 3P strand incisions is nearly equivalent for the products
on the top and bottom strands of the 5P-AGC adduct
argues that Et 743 alkylates both strands equally. The
extra incisions on the 5P-side also occurred for the se-
quence containing the 5P-AGT adduct on the top strand
(Fig. 6B, left panel), indicating that, in this case, the
anomalous incision is independent of the 3-bp Et 743 tar-
get sequence. It is surprising that the extra incisions occur
only on the top strand. The explanation must be that
Fig. 7. A: Schematic for the preparation of the Et 743 site-directed adduct. B: Reaction of the UvrABC nuclease with either a top or bottom strand
5P- or 3P-end-labeled DNA sequence containing an Et 743^DNA site-directed adduct. Modi¢cation of DNA by Et 743 was as shown for Fig. 6. The
UvrABC incision sites are indicated by arrows. AG and TC refer to Maxam^Gilbert sequencing lanes. (*) indicates the 5P-AGC alkylation site. The cen-
tral sequence shows the incision pattern for UvrABC nuclease.
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although the 5P-AGC sequences on the top and bottom
strands are both contained within an A/T-rich region, the
£anking sequences are not identical. Presumably UvrABC
is able to recognize di¡erential structural or dynamic fea-
tures between Et 743^DNA adducts on the top and bot-
tom strands. Extra 5P incisions have also been reported for
cisplatin [32], where two major incision products occurred
8 and 15 bases from the site of the lesion. However, a
more de¢ned system seemed necessary since the sequences
shown in Fig. 6A,B contained other Et 743 alkylation sites
in £anking regions, which when alkylated could poten-
tially interfere with UvrABC incision at the 5P-AGC and
5P-AGT adduct sites. Hence, we created a site-directed Et
743^DNA adduct with the same sequence as that used
above.
2.6. UvrABC incision of a DNA fragment containing
a site-directed Et 743^DNA adduct in the
preferred 5P-AGC sequence shows anomalous
cleavage
In all the previous experiments, there was potential for
overlap of UvrABC repair incision sites due to multiple Et
743^DNA adducts, and consequently the results were
sometimes di⁄cult to interpret unambiguously. In a sub-
sequent experiment, we attempted to create a more de¢ned
system. Speci¢cally, we carried out parallel UvrABC nu-
clease experiments on Et 743^DNA site-directed adducts
containing either the preferred 5P-AGC sequence or the
non-preferred 5P-AGT sequence. Since Et 743 reacts only
with duplex DNA and not single-stranded DNA, the prep-
aration and puri¢cation of Et 743^DNA adducts were
restricted to duplex DNA substrates. The strategy used
for the preparation of 5P-AGC, the site-directed adduct,
is shown in Fig. 7A. The Et 743^DNA site-directed adduct
was created by ligating a 22-bp Et 743-modi¢ed duplex
containing either a single 5P-AGC or 5P-AGT sequence
to a pair of double-stranded DNA oligonucleotides, using
di¡erent sticky ends to unambiguously ligate one on each
side of the Et 743-modi¢ed duplex. This resulted in the
construction of a 64-bp fragment containing the same se-
quence used in the prior section. While the creation of an
Et 743 site-directed adduct containing the preferred 5P-
AGC sequence was successful, repeated attempts to gen-
erate the Et 743^5P-AGT DNA adduct failed. This is pre-
sumably because the Et 743^DNA adduct at the 5P-AGT
sequence underwent covalent reversal during puri¢cation
due to its intrinsic instability [16]. Therefore, only the 64-
bp site-directed Et 743^DNA adduct containing the 5P-
AGC target sequence was used to study the pattern of
incision by UvrABC.
Fig. 7B shows the results of four experiments using both
strands having either the 3P- or 5P-radiolabeled site-di-
rected 5P-AGC adduct after incubation with the UvrABC
nuclease. 5P incision occurs both 6 and 13 bases from the
covalent attachment site on the top strand, whereas on the
bottom strand 5P incision only occurs six bases from the
Et 743 adduct site. The 3P incision events occur equally
well on both strands and show only one incision product
four bases from the Et 743-damaged guanine. The results
presented here substantiate our previous results (shown in
Fig. 6A), in which anomalous incision occurs only on the
top strand on the 5P-side, while the incision occurs on the
bottom strand at the expected sites, i.e. six bases 5P and
four bases 3P to the Et 743-alkylated guanine, for a DNA
duplex containing a 5P-AGC sequence.
3. Discussion
Et 743 is a structurally and mechanistically unique anti-
tumor antibiotic that has shown very encouraging antitu-
mor activity in phase I and II clinical trials, particularly in
soft tissue sarcomas. Because of the implications of the
involvement of NER in mediating the biological potency,
and perhaps speci¢city, of this compound (see Fig. 3), we
set out to study the recognition and incision of Et 743^
DNA adducts using the Escherichia coli UvrABC nucle-
ase. While the human NER system is more complex, in-
volving a larger number of repair proteins, and the repair
patch is larger than in the bacterial system, the basic
mechanism is similar in both systems. In the UvrABC
system, repair is initiated by the UvrA protein, which di-
merizes prior to formation of a heterotrimeric complex
with UvrB [33,34]. This UvrA2B complex has helicase-
like properties and speci¢cally binds to damaged DNA
[35,36]. Binding of the UvrA2B complex to duplex DNA
results in both bending of the DNA and an open DNA
structure [35,37,38]. After damage recognition, UvrA dis-
sociates, while UvrB remains bound to the damaged DNA
in a stable preincision complex [39,40]. Following the
binding of UvrC to this complex, incision is triggered on
both sides of the damaged site: four nucleotides 3P to the
damaged site and seven nucleotides 5P to the same site
[37,41^43]. The repair is completed by UvrD, DNA poly-
merase, and DNA ligase. Much remains to be learned
about the structural biology of the discrimination between
non-damaged and damaged DNA and the structures of
the various complexes of UvrA2, UvrA2B^DNA, UvrB^
DNA, and UvrBC^DNA. A crystal structure of UvrB has
recently been published and a model of the UvrB^DNA
complex has been proposed [36]. We propose a model for
how Et 743^DNA adducts are processed by bacterial and
human cells to result in the repair-dependent toxicity to
cells. This model takes into account both the unique struc-
tural and dynamic features of the Et 743^DNA adducts
and the resistance of mammalian cells to the toxic e¡ects
of Et 743, which are defective in NER repair proteins
involved in assembly of a repair complex competent to
perform 3P and 5P incision steps.
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3.1. The e⁄ciency of UvrABC incision of Et 743^DNA
adducts is dependent upon the stability of the bound
adduct at the target sequence, and in some cases, the
3P and 5P incisions are absent or they occur at
aberrant sites
There is a clear di¡erence in the e⁄ciency of the
UvrABC incision of Et 743^DNA adducts that is depen-
dent upon the precise Et 743 bonding sequence. The re-
sults summarized in Fig. 5A,B show that Et 743^DNA
adducts bound to 5P-AGT sequences are much more e⁄-
ciently incised by UvrABC nuclease than the same adducts
bound to 5P-AGC sequences. In a previous study [16] we
demonstrated that the presence or absence of speci¢c hy-
drogen-bonding interactions between donors and accep-
tors on Et 743 and the 3-bp recognition sequence leads
to signi¢cant di¡erences in the stability and conformation-
al £exibility of the resulting DNA adducts. Of prime im-
portance is the presence or absence of a hydrogen-bonding
interaction between O18 of the methylenedioxy ring and
the exocyclic 2-amino group of guanine on the 3P-side of
the alkylated guanine, which may be on either the covalent
or non-covalently modi¢ed strand (see Fig. 1B). Of less
signi¢cance are the hydrogen-bonding interactions on the
5P-side of the covalently modi¢ed guanine. In the absence
of a 3P GC base pair, which provides this crucial hydro-
gen-bonding, Et 743^DNA adducts more easily undergo
covalent reversal and show weaker base-pairing forms and
alternative base-pairing conformers on the 5P-side [16].
Furthermore, as anticipated, helicase-catalyzed unwinding
of DNA using T-antigen or thermal denaturation results
in enhanced instability of the Et 743^5P-AGT duplex ad-
ducts over the corresponding 5P-AGC duplex adducts [16].
Therefore, there is an inverse correlation between Et 743^
Fig. 8. Proposed model for how UvrABC nuclease may process Et 743^DNA adducts, leading to either a repaired lesion (pathway ‘a’) or a toxic lesion
(pathway ‘b’) corresponding to the mammalian NER-dependent toxicity. In pathway ‘a’, UvrA2B is able to recognize the Et 743 and unwind the duplex
DNA, creating the bubble that positions the Et 743^DNA adduct in a region of single-strandness, which leads to covalent reversal of the Et 743^DNA
adduct (aP) or to 3P and 5P incisions (aQ). For pathway ‘b’, an optimally stabilized Et 743^DNA adduct is in a region of bent DNA, which is recognized
and bound by the UvrA2B complex. In this case the Et 743^DNA duplex adduct mimics the normally unwound form of modi¢ed DNA bound to
UvrA2B, A2 dissociates, and then C binds to form the Et 743^BC complex. This substrate is ine⁄ciently incised by UvrBC, which results in the absence
of 3P and 5P incisions. This leads to the toxic lesion mechanistically equivalent to a drug-poisoned topoisomerase I^ or topoisomerase II^DNA complex.
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DNA adduct stability and UvrABC incision e⁄ciency.
This point is further exempli¢ed by a comparison of the
UvrABC incision e⁄ciency of Et 743^5P-AGT adducts in
di¡erent sequence contexts. Et 743^5P-AGT adducts adja-
cent to A-tracts are much less e⁄ciently incised than the
same adducts without £anking A-tracts. In a previous
study [16] we demonstrated that A-tracts stabilize Et
743^DNA adducts to covalent reversal, which we have
attributed to dampening the conformational £exibility of
Et 743^5P-AGT adducts and strengthening the apparent
hydrogen-bonding interactions.
Irrespective of the covalent bonding sequence, Et 743^
DNA adducts appeared to show some uncoupled 3P and 5P
incisions (Fig. 5A,B), although the combination of the low
frequency of these events and their sometimes ambiguous
assignment makes this conclusion less than ¢rm. The ab-
sence of both 3P and 5P incisions is found only for the 5P-
AGC Et 743 bonding sequences. Thus it would appear
that for loss of both 3P and 5P incisions, the hydrogen-
bonding donor/acceptor pair between Et 743 and the GC
base pair immediately to the 3P-side of the Et 743^DNA
adduct is required. Last, aberrant UvrABC incisions oc-
curring 11 or 13 bases to the 5P-side of the Et 743^DNA
adducts are found for both 5P-AGT and 5P-AGC bonding
sites.
3.2. Ine⁄cient 3P and 5P incisions by NER complexes lead
to cytotoxic e¡ects of Et 743^DNA adducts in
human cells
In contrast to the E. coli UvrABC nuclease, where the
UvrC and UvrB proteins give rise to the 5P and 3P inci-
sions, in human NER the dual incisions at the 5P- and 3P-
sides of the DNA adducts are carried out by two physi-
cally separated nuclease activities : XPG^ and XPF^
ERCC1, respectively. Human cells lacking either of these
nucleases are resistant to Et 743 [23,24]. Furthermore, the
results in Fig. 3 show that other defective proteins in-
volved in the formation of the NER nuclease complex
also show resistance to Et 743. Therefore, any model of
how Et 743 exerts its cytotoxic potency via the NER path-
way must take into account how this NER nuclease com-
plex might result in structural consequences that are det-
rimental to cell survival.
3.3. In addition to a sequence-dependent hydrogen-bonding
stabilization of the Et 743^DNA adduct, Et 743^DNA
adducts have other unique structural e¡ects on DNA
NMR studies on covalent oligomer duplex adducts of
Et 743 and non-denaturing PAGE analysis of ligated olig-
omers containing de¢ned Et 743^DNA adducts reveal im-
portant novel characteristics of Et 743^DNA adducts.
While Et 743 modi¢es duplex DNA within the minor
groove (Fig. 2A), it also bends DNA into the major
groove [19]. This results from the wedge shape of Et
743, which forces open the minor groove of DNA and
concomitantly closes up the major groove. In addition to
the major groove bending and minor groove occupancy,
the C-subunit of Et 743 protrudes outside the helical axis
occupied by duplex DNA (Fig. 2A). In summary, the co-
valent attachment of Et 743 to DNA and £anking donor/
acceptor hydrogen-bonding of DNA zipper up a locally
widened minor groove of DNA, which also has an extra-
helical protrusion in an otherwise bent DNA. Somehow
these unique structural characteristics of Et 743^DNA ad-
ducts must result in the reduced e⁄ciencies of the se-
quence-dependent UvrABC nuclease incision and the un-
coupled or absent 3P and 5P UvrABC incisions observed in
this study, along with the NER-dependent cytotoxicities
observed in human cells. In Section 3.4 we propose a
model that takes into account all of these observations
with what is known about NER in E. coli and human
cells.
3.4. Model for how the inhibited repair of Et 743^DNA
adducts can lead to NER-mediated cytotoxicity
As previously described, UvrA2B complex detection of
damaged DNA is proposed to lead to a 6-bp bubble
around the modi¢ed based and to bending of the DNA
[35]. This then results in dissociation of UvrA2 from the
complex, leaving a UvrB^DNA complex that is a stable
preincision complex. UvrC is then recruited, which results
in endonuclease cleavage by UvrC 3P and 5P to the adduct
site [44] (see pathways ‘a’ and ‘aQ’ in Fig. 8). Dependent
upon the stability of the Et 743^N2-guanine DNA adduct
in the 6-bp bubble, the Et 743^N2-guanine covalent link-
age may reverse before the 3P and 5P incisions occur (path-
ways ‘a’ and ‘aP’ in Fig. 8). These pathways are most likely
in the unfavored sequences for Et 743^DNA adduct stabil-
ity, where bubble formation is most likely, due to the lack
of the additional H-bonding 5P to the covalently modi¢ed
guanine (see Fig. 1B). Neither pathway ‘a’ scenario would
be predicted to give rise to the repair-dependent enhanced
toxicities observed in mammalian cells.
However, processing of Et 743^DNA lesions by path-
way ‘b’ (Fig. 8) is predicted to give rise to a toxic lesion.
We propose that the unique properties of speci¢c Et 743^
DNA adducts lead to malfunction of the UvrABC nucle-
ase system, leading to ine⁄cient incisions on both the 3P-
and 5P-sides and, in some cases, possibly uncoupled 3P and
5P incisions. Why does an encounter between the UvrABC
nuclease system and the hydrogen-bonded stabilized Et
743^DNA adduct lead to aberrant DNA repair?
First, Et 743^DNA adducts may be particularly di⁄cult
to process because of their resistance to the helicase activ-
ity of the UvrA2B complex, primarily arising from the
zipper-like e¡ects of the hydrogen-bonding stabilization
on both sides of the covalent adduct. This is analogous
to resistance of stable Et 743^DNA adducts to T-antigen
unwinding [16].
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It is most likely to be those Et 743^DNA adducts that
are resistant to the helicase activity of UvrA2B that lead to
the excision-dependent cytotoxicity (i.e. Et 743^DNA ad-
ducts at preferred sequences). In order for incision to oc-
cur, UvrA must dissociate and the stable preincision com-
plex of UvrB must be recognized by UvrC to form the
active UvrBC nuclease (pathway ‘b’ in Fig. 8).
Second, we propose that the stable Et 743^DNA duplex
adducts must have structural features that somehow mimic
the bent and open form of the normal UvrA2B heterotri-
meric complex with DNA. Indeed, Et 743^DNA adducts
are bent into the major groove through minor groove ex-
pansion due to occupancy by the wedge-shaped Et 743.
The extrahelical protrusion of the C-subunit of Et 743
may also play a role in promoting the dissociation of
UvrA and, perhaps, stabilizing the UvrB preincision com-
plex. However, in the absence of de¢ned structural inter-
actions among the various protein^DNA components of
the UvrA2B^, UvrB^, and UvrBC^DNA complexes, it is
impossible to be more speci¢c than just suggesting possible
structural mimics (bending) and steric interactions (extra-
helical protrusion) that could lead to aberrant DNA repair
outcomes. One could envisage a situation similar to that of
a drug-poisoned topoisomerase I or II complex where a
drug molecule intercepts an intermediate in which neither
a 3P nor a 5P incision is made but the UvrBC, or even the
UvrABC, is trapped as a non-covalent protein^Et 743^
DNA complex, which is more detrimental to cells than
the original Et 743^DNA adduct. Just as with the drug-
poisoned topoisomerase I or II complexes, where elevated
levels of topoisomerases would lead to populations of
more susceptible cells, a similar situation exists for ele-
vated levels of NER proteins. Some of these possibilities
are being explored.
4. Signi¢cance
The pattern of ine⁄cient repair incision by the UvrABC
nuclease of Et 743^DNA adducts provides a basis for
rationalizing the observed repair-dependent cytotoxicities
of these DNA adducts, if other associated structural prop-
erties of Et 743^DNA adducts are taken into account. On
the basis of promising activity in phase I clinical trials, Et
743 has progressed into phase II clinical trials, where it has
shown remarkable activity in soft tissue sarcomas. This is
the ¢rst of the monoalkylating minor groove-interactive
agents to progress beyond phase I clinical trials. In pre-
vious studies we have determined the structure of the Et
743^DNA covalent adduct, its e¡ect on DNA structure,
and the hydrogen-bonding interactions, which determine
DNA sequence selectivity and enhanced stability on DNA.
These properties set Et 743 apart from other minor groove
alkylating compounds. Recent results from groups in Italy
(D’Incalci lab) and at NCI (Pommier lab) provide insight
into the molecular targets for Et 743, which appear to be
proteins involved in the NER pathway. We have con-
¢rmed this conclusion, but what is most signi¢cant is
that we have identi¢ed what is likely to be the structural
and biochemical basis for the NER-dependent cytotoxicity
of the Et 743^DNA adducts. These results link the struc-
tural biology of the Et 743^DNA adducts with the biolog-
ical consequences of incomplete DNA repair. This result is
somewhat reminiscent of the formation of cleavable com-
plexes with topoisomerase I^ and topoisomerase II^DNA
adducts.
5. Materials and methods
5.1. Materials
Ecteinascidin was generously supplied by PharmaMar, Madrid,
Spain.
5.2. Cell lines and culture conditions
The Chinese hamster ovary parent cell line (AA8) and the
NER-defective cell lines XPB, XPD, XPF, XPG, and ERCC1
were purchased from American Type Culture Collection. All cell
lines were grown as a monolayer in Dulbecco’s modi¢ed Eagle’s
medium (Gibco, #10-013-CV) supplemented with 1% (v/v) penicil-
lin (100 U/ml), streptomycin (100 Wg/ml), and 10% fetal bovine
serum. Cells were grown at 37‡C in a 5% CO2 humidi¢ed incu-
bator. Trypsin^EDTA solution was used for detaching cells.
5.3. Cytotoxicity assay
A colorimetric assay based on the ability of viable cells to
reduce the tetrazolium salt MTS (CellTiter 96 Non-Radioactive
Cell Proliferation Assay, Promega Corp., Madison, WI, USA) to
a blue formazan product was used to measure cytotoxicity fol-
lowing exposure to Et 743. Cells were plated in a 0.1 ml medium
on day 0 in 96-well microtiter plates (Falcon, #3072). On day 1,
10 Wl of serial dilutions of the test agent was added in replicates
of four to the plates. After incubation for 4 days at 37‡C in a
humidi¢ed incubator, 2 Wl of a 20:1 mixture of 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt MTS (2 mg/ml) and an electron coupling
reagent, phenazine methosulfate (0.92 mg/ml in DPBS), was
added to each well and incubated for 4 h at 37‡C. Absorbance
was measured using a Model 7520 microplate reader (Cambridge
Technology, Inc.) at 490 nm. Data were expressed as the percent-
age of survival of control calculated from the absorbance cor-
rected for background absorbance. The surviving fraction of cells
was determined by dividing the mean absorbance values of the
test agents by the mean absorbance values of untreated control.
5.4. Et 743^DNA bonding
Speci¢c amounts of drug were added to radiolabeled DNA in
10 mM Tris^HCl (pH 7.5) and 25 mM NaCl bu¡er to give the
desired ¢nal concentration. The solutions were incubated at room
temperature for either 1 or 2 h. The unreacted drug was removed
by phenol^chloroform extraction.
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5.5. Puri¢cation of UvrABC proteins
UvrA, UvrB, and UvrC proteins were isolated from E. coli
K12 strain CH292 carrying plasmids pUNC45 (UvrA),
pUNC211 (UvrB), and pDR3274 (UvrC) [45]. The methods of
puri¢cation were the same as described previously [46]. For the
experiments using the DNA fragments from the pCAT and
pBR322 plasmids, the UvrABC proteins were purchased from
PharMingen (San Diego, CA, USA).
5.6. DNA fragment isolation and 32P-end-labeling
Plasmid pGEM inserted with APRT gene from Chinese ham-
ster ovary cells was puri¢ed via cesium chloride density centrifu-
gation and dialyzed extensively against TE bu¡er. The 284-bp
fragment of exon III of the APRT gene was obtained by digesting
plasmid DNA with restriction enzymes PstI and StuI. The band
corresponding to the 284-bp fragment was isolated from 1.4%
agarose gel and cleaned by passing through a NACS Prepac
column followed by ethanol precipitation. The 284-bp fragment
was further cut with the restriction enzyme MseI to generate a
188-bp fragment with a unique site for a single 3P-end-labeling.
DNA labeling was accomplished in the presence of [K-32P]TTP
and Klenow fragment (5 U) in 10 mM Tris^HCl (pH 8.0), 5 mM
MgCl2, and 7.5 mM dithiothreitol (DTT) at 22‡C. The 3P-end-
labeled fragment was puri¢ed on a 5% polyacrylamide gel. For
5P-end-labeling, the restriction enzyme HinfI was used to cut the
284-bp fragment to create protruding 5P termini. The resulting
fragment was treated with bacterial alkaline phosphatase at
60‡C for 1 h. The dephosphorylated fragment was extracted
with phenol^chloroform and puri¢ed by gel electrophoresis.
The puri¢ed fragment was then labeled with [Q-32P]ATP in the
presence of T4 polynucleotide kinase. The labeled fragment was
precipitated with ethanol and digested with MseI to a¡ord a 170-
bp 5P-end-labeled fragment, which was then isolated and puri¢ed
as above.
For the isolation of a 209-bp fragment labeled at the 5P-end
with 32P, the pCAT plasmid (New England Biolabs) was ¢rst
digested with HindIII followed by treatment with shrimp alkaline
phosphatase at 37‡C for 2 h. The dephosphorylated fragment was
extracted with phenol^chloroform and then ethanol-precipitated.
The precipitated DNA was labeled with [Q-32P]ATP in the pres-
ence of T4 polynucleotide kinase. The labeled DNA was then
incubated with EcoRI and gel-puri¢ed to yield the 209-bp 5P-
end-labeled fragment. For 3P-end-labeling, the restriction enzyme
EcoRI was used to cut the pCAT plasmid. DNA labeling was
accomplished in the presence of [K-32P]ATP and Klenow frag-
ment. The 3P-end-labeled DNA was then incubated with HindIII
and puri¢ed on a 6% polyacrylamide gel. The same protocol was
used to generate a 200-bp fragment from the pBR322 plasmid
(New England Biolabs) except the restriction enzymes NheI and
BamHI were used.
5.7. Construction of the Et 743^DNA adducts
The 22-bp duplex DNA [(5P-TGGTTATATAAGCTATTA-
TAAT-3P)(3P-ATATATTCGATAATATTAGCTC-5P)] contain-
ing a single 5P-AGC alkylation site was modi¢ed with 20 WM
Et 743 for 2 h. Unreacted drug was removed by phenol^chloro-
form extraction followed by ethanol precipitation. The Et 743-
modi¢ed DNA was ligated to a radiolabeled duplex DNA, on
either the 5P- or 3P-side, by incubating with T4 DNA ligase (1 U/
100 Wl) at 16‡C for 12 h. After gel puri¢cation, the resulting Et
743-modi¢ed duplex was ligated to another duplex, on either the
3P- or 5P-side of the modi¢ed DNA fragment. The site-directed
adduct was gel-puri¢ed and eluted in annealing bu¡er.
5.8. UvrABC nuclease reactions
The UvrABC nuclease reactions were carried out in a reaction
mixture (30 Wl) containing 50 mM Tris^HCl (pH 7.5), 0.1 mM
EDTA, 10 mM MgCl2, 1 mM ATP, 100 mM KCl, 1 mM DTT,
60 nM UvrA, 120 nM UvrB, 60 nM UvrC, and substrate DNA.
The mixtures were incubated at 37‡C for 1 h and the reactions
were stopped by phenol^chloroform extraction followed by etha-
nol precipitation in the presence of aqueous ammonium acetate
(2.5 M). The precipitated DNA was recovered by centrifugation
and washed with 80% ethanol.
For the DNA fragments isolated from the pCAT and pBR322
plasmids, the UvrABC nuclease reactions were carried out in a
reaction mixture (20 Wl) containing 50 mM Tris^HCl (pH 7.5), 10
mM MgCl2, 2 mM ATP, 50 mM KCl, 5 mM DTT, 0.1 mg/ml
bovine serum albumin, 10 nM UvrA, 80 nM UvrB, 12 nM UvrC,
and substrate DNA. The mixtures were incubated at 37‡C for 1 h
and then precipitated with ethanol. The samples were loaded on
an 8% denaturing sequencing gel.
6. Note added in proof
In the recently published paper by Takebayashi et al.
[23], there is demonstration of accumulation of DNA sin-
gle-strand breaks in transcription-coupled (TC) NER-pro-
¢cient ¢broblasts treated with Et 743. Thus, our observa-
tion of a low frequency of uncoupled 3P or 5P incisions
may be of signi¢cance. The conclusion in this paper that
‘trapping of the TC-NER complex stalled [during or] after
DNA cleavage’ is exactly in accord with our results and
conclusions. This ¢nding is similar to that reported for
phleomycin [47], anthramycin [25], and ditercalinium [48].
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